Immunohistochemically determined estrogen receptor phenotype remains stable in recurrent and metastatic breast cancer

Carmen Gomez-Fernandez, Yahya Daneshbod, Mehdi Nassiri, Clara Milikowski, Consuelo Alvarez, Mehrdad Nadji

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

We evaluated the estrogen receptor (ER) phenotype of recurrent and/or metastatic breast cancers and compared it with the ER status of the primary tumor in 278 cases. All patients had undergone surgical excision of the primary tumor, followed by observation only or treatment modalities that included radiation and/or chemotherapy or hormonal therapy. The immunohistochemical expression of ER was evaluated by using monoclonal antibody ER-1D5 and heat-induced antigen retrieval. At diagnosis, 165 patients had locoregional disease and 7 had distant metastases. Local recurrences and/or distant metastases occurred from 2 months to 21 years after the diagnosis of the primary tumor. Overall, 159 primary tumors (57.2%) were positive for ER. In 269 cases (96.8%), the ER status of the primary and metastatic tumors was the same. In 9 patients with ER+ primary tumors, the metastases were ER-. There were no ER- primary tumors with ER+ metastases. The time to distant metastasis was significantly longer for ER+ tumors. The immunohistochemically determined ER phenotype of primary breast cancers remains stable in most recurrent and metastatic disease.

Original languageEnglish
Pages (from-to)879-882
Number of pages4
JournalAmerican Journal of Clinical Pathology
Volume130
Issue number6
DOIs
StatePublished - Dec 1 2008

Fingerprint

Estrogen Receptors
Breast Neoplasms
Phenotype
Neoplasm Metastasis
Neoplasms
Hot Temperature
Monoclonal Antibodies
Observation
Radiation
Antigens
Recurrence
Drug Therapy

Keywords

  • Breast cancer
  • Estrogen receptor
  • Immunohistochemistry
  • Metastatic breast carcinoma

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Immunohistochemically determined estrogen receptor phenotype remains stable in recurrent and metastatic breast cancer. / Gomez-Fernandez, Carmen; Daneshbod, Yahya; Nassiri, Mehdi; Milikowski, Clara; Alvarez, Consuelo; Nadji, Mehrdad.

In: American Journal of Clinical Pathology, Vol. 130, No. 6, 01.12.2008, p. 879-882.

Research output: Contribution to journalArticle

@article{c716214540e4402794268ff5594ff626,
title = "Immunohistochemically determined estrogen receptor phenotype remains stable in recurrent and metastatic breast cancer",
abstract = "We evaluated the estrogen receptor (ER) phenotype of recurrent and/or metastatic breast cancers and compared it with the ER status of the primary tumor in 278 cases. All patients had undergone surgical excision of the primary tumor, followed by observation only or treatment modalities that included radiation and/or chemotherapy or hormonal therapy. The immunohistochemical expression of ER was evaluated by using monoclonal antibody ER-1D5 and heat-induced antigen retrieval. At diagnosis, 165 patients had locoregional disease and 7 had distant metastases. Local recurrences and/or distant metastases occurred from 2 months to 21 years after the diagnosis of the primary tumor. Overall, 159 primary tumors (57.2{\%}) were positive for ER. In 269 cases (96.8{\%}), the ER status of the primary and metastatic tumors was the same. In 9 patients with ER+ primary tumors, the metastases were ER-. There were no ER- primary tumors with ER+ metastases. The time to distant metastasis was significantly longer for ER+ tumors. The immunohistochemically determined ER phenotype of primary breast cancers remains stable in most recurrent and metastatic disease.",
keywords = "Breast cancer, Estrogen receptor, Immunohistochemistry, Metastatic breast carcinoma",
author = "Carmen Gomez-Fernandez and Yahya Daneshbod and Mehdi Nassiri and Clara Milikowski and Consuelo Alvarez and Mehrdad Nadji",
year = "2008",
month = "12",
day = "1",
doi = "10.1309/AJCPD1AO3YSYQYNW",
language = "English",
volume = "130",
pages = "879--882",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "6",

}

TY - JOUR

T1 - Immunohistochemically determined estrogen receptor phenotype remains stable in recurrent and metastatic breast cancer

AU - Gomez-Fernandez, Carmen

AU - Daneshbod, Yahya

AU - Nassiri, Mehdi

AU - Milikowski, Clara

AU - Alvarez, Consuelo

AU - Nadji, Mehrdad

PY - 2008/12/1

Y1 - 2008/12/1

N2 - We evaluated the estrogen receptor (ER) phenotype of recurrent and/or metastatic breast cancers and compared it with the ER status of the primary tumor in 278 cases. All patients had undergone surgical excision of the primary tumor, followed by observation only or treatment modalities that included radiation and/or chemotherapy or hormonal therapy. The immunohistochemical expression of ER was evaluated by using monoclonal antibody ER-1D5 and heat-induced antigen retrieval. At diagnosis, 165 patients had locoregional disease and 7 had distant metastases. Local recurrences and/or distant metastases occurred from 2 months to 21 years after the diagnosis of the primary tumor. Overall, 159 primary tumors (57.2%) were positive for ER. In 269 cases (96.8%), the ER status of the primary and metastatic tumors was the same. In 9 patients with ER+ primary tumors, the metastases were ER-. There were no ER- primary tumors with ER+ metastases. The time to distant metastasis was significantly longer for ER+ tumors. The immunohistochemically determined ER phenotype of primary breast cancers remains stable in most recurrent and metastatic disease.

AB - We evaluated the estrogen receptor (ER) phenotype of recurrent and/or metastatic breast cancers and compared it with the ER status of the primary tumor in 278 cases. All patients had undergone surgical excision of the primary tumor, followed by observation only or treatment modalities that included radiation and/or chemotherapy or hormonal therapy. The immunohistochemical expression of ER was evaluated by using monoclonal antibody ER-1D5 and heat-induced antigen retrieval. At diagnosis, 165 patients had locoregional disease and 7 had distant metastases. Local recurrences and/or distant metastases occurred from 2 months to 21 years after the diagnosis of the primary tumor. Overall, 159 primary tumors (57.2%) were positive for ER. In 269 cases (96.8%), the ER status of the primary and metastatic tumors was the same. In 9 patients with ER+ primary tumors, the metastases were ER-. There were no ER- primary tumors with ER+ metastases. The time to distant metastasis was significantly longer for ER+ tumors. The immunohistochemically determined ER phenotype of primary breast cancers remains stable in most recurrent and metastatic disease.

KW - Breast cancer

KW - Estrogen receptor

KW - Immunohistochemistry

KW - Metastatic breast carcinoma

UR - http://www.scopus.com/inward/record.url?scp=58049217550&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58049217550&partnerID=8YFLogxK

U2 - 10.1309/AJCPD1AO3YSYQYNW

DO - 10.1309/AJCPD1AO3YSYQYNW

M3 - Article

VL - 130

SP - 879

EP - 882

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 6

ER -